Novartis and Clarius Partnership for Psoriatic Arthritis

Novartis Pharmaceuticals Canada Inc. has announced a partnership with Clarius Mobile Health to improve early detection of psoriatic arthritis (PsA) in Canada. By enhancing access to handheld ultrasound technology, rheumatologists can identify diagnostic markers sooner, potentially reducing the time to diagnosis for patients. This collaboration aims to transform PsA detection and improve patient outcomes through innovative medical imaging solutions.